Hengrui Medicine gains approval for SHR-4712 clinical trials

Jiangsu Hengrui Medicine Co., Ltd. (SSE:600276) announced that its subsidiaries, Guangdong Hengrui Pharmaceutical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration to conduct clinical trials for SHR-4712 injection, a Class 1 therapeutic biological product. The trials will focus on advanced solid tumors. SHR-4712 is designed to target tumor-associated antigens, stimulate immune cells within the tumor microenvironment, and exert anti-tumor effects. As of now, there are no similar drugs approved for marketing, either domestically or internationally. Hengrui Medicine has invested approximately CNY 2,492,000 into related projects for SHR-4712. The company cautioned investors about the uncertainties involved in drug development, including clinical trial outcomes and regulatory approvals.